C. Röllig, S. Knop, M. Bornhäuser, . Multiple, and . Myeloma, Lancet, vol.385, pp.2197-2208, 2015.

D. Kazandjian, Multiple myeloma epidemiology and survival: A unique malignancy, Semin. Oncol, vol.43, pp.676-681, 2016.

S. V. Rajkumar, M. A. Dimopoulos, A. Palumbo, J. Bladé, G. Merlini et al., International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma, Lancet Oncol, vol.15, pp.538-548, 2014.

B. Nandakumar, M. Binder, A. Dispenzieri, P. Kapoor, F. Buadi et al., Continued improvement in survival in multiple myeloma (MM) including high-risk patients, J. Clin. Oncol, vol.37, 2019.

C. H. Blimark, I. Turesson, A. Genell, L. Ahlberg, B. Björkstrand et al., Outcome and survival of myeloma patients diagnosed 2008-2015. Real-world data on 4904 patients from the Swedish Myeloma Registry, vol.103, pp.506-513, 2017.

A. Branagan, M. Lei, U. Lou, and N. Raje, Current Treatment Strategies for Multiple Myeloma, JCO Oncol. Pr, vol.16, pp.5-14, 2020.

C. Bailly, P. Cléry, A. Faivre-chauvet, M. Bourgeois, F. Guérard et al., Immuno-PET for Clinical Theranostic Approaches, Int. J. Mol. Sci, vol.18, 2016.
URL : https://hal.archives-ouvertes.fr/in2p3-01951323

G. Rolfe, D. Freshwater, and M. Jasper, Critical Reflection for Nursing and the Helping Professions: A User's Guide

. Palgrave, , 2001.

N. Giuliani and F. Malavasi, Immunotherapy in Multiple Myeloma. Front. Immunol, vol.10, 1945.

C. Touzeau, P. Moreau, and C. Dumontet, Monoclonal antibody therapy in multiple myeloma, Leukemia, vol.31, pp.1039-1047, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01795709

M. Mateos, M. A. Dimopoulos, M. Cavo, K. Suzuki, A. Jakubowiak et al., Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma, N. Engl. J. Med, vol.378, pp.518-528, 2018.

P. Moreau, M. Attal, C. Hulin, B. Arnulf, K. Belhadj et al., Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): A randomised, open-label, phase 3 study, Lancet, vol.394, pp.29-38, 2019.

M. A. Dimopoulos, A. Oriol, H. H. Nahi, J. San-miguel, N. J. Bahlis et al., Lenalidomide, and Dexamethasone for Multiple Myeloma, New Engl. J. Med, vol.375, pp.1319-1331, 2016.

A. Palumbo, A. Chanan-khan, K. Weisel, A. K. Nooka, T. Masszi et al., Bortezomib, and Dexamethasone for Multiple Myeloma, N. Engl. J. Med, vol.375, pp.754-766, 2016.

E. Zamagni, P. Tacchetti, L. Pantani, M. Cavo, and -. Anti, The future of myeloma immunotherapy, Expert Rev. Hematol, vol.11, pp.423-435, 2018.

S. Lonial, B. Durie, A. Palumbo, and J. San-miguel, Monoclonal antibodies in the treatment of multiple myeloma: Current status and future perspectives, Leukemia, vol.30, pp.526-535, 2015.

T. Plesner and J. Krejcik, Daratumumab for the Treatment of Multiple Myeloma, Front. Immunol, vol.9, issue.9, 2018.

S. Afifi, A. Michael, and A. Lesokhin, Immunotherapy. Ann. Pharmacother, vol.50, pp.555-568, 2016.

N. W. Van-de-donk, P. G. Richardson, and F. Malavasi, CD38 antibodies in multiple myeloma: Back to the future, Blood, vol.131, pp.13-29, 2018.

M. Dostalek, I. Gardner, B. M. Gurbaxani, R. H. Rose, M. Chetty et al., Pharmacodynamics and Physiologically-Based Pharmacokinetic Modelling of Monoclonal Antibodies, Clin. Pharm, vol.52, pp.83-124, 2013.

R. J. Keizer, A. D. Huitema, J. H. Schellens, and J. H. Beijnen, Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies, vol.49, pp.493-507, 2010.

M. Ahamadi, T. Freshwater, M. Prohn, C. H. Li, D. P. De-alwis et al., Model-Based Characterization of the Pharmacokinetics of Pembrolizumab: A Humanized Anti-PD-1 Monoclonal Antibody in Advanced Solid Tumors, CPT Pharmacomet. Syst. Pharmacol, vol.6, pp.49-57, 2016.

G. Bajaj, X. Wang, S. Agrawal, M. Gupta, A. Roy et al., Model-Based Population Pharmacokinetic Analysis of Nivolumab in Patients With Solid Tumors, CPT Pharmacomet. Syst. Pharmacol, vol.6, pp.58-66, 2016.

K. Ogungbenro, A. Patel, R. Duncombe, R. Nuttall, J. Clark et al., Dose Rationalization of Pembrolizumab and Nivolumab Using Pharmacokinetic Modeling and Simulation and Cost Analysis, Clin. Pharmacol. Ther, vol.103, pp.582-590, 2017.

P. L. Clemens, X. Yan, H. M. Lokhorst, S. Lonial, N. Losic et al., Pharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma After Prior Proteasome Inhibitor and Immunomodulatory Drug Treatment, Clin. Pharm, vol.56, pp.915-924, 2017.

X. S. Xu, X. Yan, T. Puchalski, S. Lonial, H. M. Lokhorst et al., Clinical Implications of Complex Pharmacokinetics for Daratumumab Dose Regimen in Patients With Relapsed/Refractory Multiple Myeloma, Clin. Pharmacol. Ther, vol.101, pp.721-724, 2017.

N. W. Van-de-donk and S. Z. Usmani, CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance, Front. Immunol, vol.9, issue.9, 2018.

P. Mogollón, A. Díaz-tejedor, E. Algarín, T. Paíno, M. Garayoa et al., Biological Background of Resistance to Current Standards of Care in Multiple Myeloma, Cells, vol.8, 1432.

S. Oliva, R. Troia, M. D'agostino, M. Boccadoro, and F. Gay, Promises and Pitfalls in the Use of PD-1/PD-L1 Inhibitors in Multiple Myeloma, Front. Immunol, vol.9, p.2749, 2018.

J. Rosenblatt and D. Avigan, Targeting the PD-1/PD-L1 axis in multiple myeloma: A dream or a reality? Blood, vol.129, pp.275-279, 2017.

H. Tamura, M. Ishibashi, T. Yamashita, S. Tanosaki, N. Okuyama et al., Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma, Leukemia, vol.27, pp.464-472, 2012.

T. Jelinek, B. Paiva, and R. Hajek, Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma, Front. Immunol, vol.9, p.2431, 2018.

F. Costa, R. Das, J. K. Bailur, K. Dhodapkar, and M. V. Dhodapkar, Checkpoint Inhibition in Myeloma: Opportunities and Challenges. Front. Immunol, vol.9, 2018.

B. Paiva, A. Azpilikueta, N. Puig, E. M. Ocio, R. Sharma et al., Aires-Mejía, I.; et al. PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma, Leukemia, vol.29, pp.2110-2113, 2015.

A. M. Lesokhin, S. M. Ansell, P. Armand, E. C. Scott, A. Halwani et al., Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study, J. Clin. Oncol, vol.34, pp.2698-2704, 2016.

V. Ribrag, D. E. Avigan, D. J. Green, T. Wise-draper, J. G. Posada et al., Phase 1b trial of pembrolizumab monotherapy for relapsed/refractory multiple myeloma: KEYNOTE-013, Br. J. Haematol, vol.186, pp.41-44, 2019.

M. Mateos, R. Z. Orlowski, E. M. Ocio, P. Rodríguez-otero, N. Reece et al., Pembrolizumab combined with lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: Phase I KEYNOTE -023 study, Br. J. Haematol, vol.186, pp.117-121, 2019.

S. Z. Usmani, F. Schjesvold, A. Oriol, L. Karlin, M. Cavo et al., Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): A randomised, open-label, phase 3 trial, Lancet Haematol, vol.6, pp.448-458, 2019.

M. Mateos, H. Blacklock, F. Schjesvold, A. Oriol, D. Simpson et al., Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): A randomised, open-label, phase 3 trial, Lancet Haematol, vol.6, pp.459-469, 2019.

C. Costello, The future of checkpoint inhibition in multiple myeloma?, Lancet Haematol, vol.6, pp.439-440, 2019.

C. Zelle-rieser, S. Thangavadivel, R. Biedermann, A. Brunner, P. Stoitzner et al., T cells in multiple myeloma display features of exhaustion and senescence at the tumor site, J. Hematol. Oncol, vol.9, p.116, 2016.

T. N. Schumacher and R. D. Schreiber, Neoantigens in cancer immunotherapy, Science, vol.348, pp.69-74, 2015.

S. Danhof, S. Strifler, D. Hose, M. Kortüm, M. Bittrich et al., Clinical and biological characteristics of myeloma patients influence response to elotuzumab combination therapy, J. Cancer Res. Clin. Oncol, vol.145, pp.561-571, 2018.

A. Jakubowiak, M. Offidani, B. Pegourie, J. De-la-rubia, L. Garderet et al., Randomized phase 2 study: Elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM, Blood, vol.127, pp.2833-2840, 2016.

I. S. Nijhof, T. Casneuf, J. Van-velzen, B. Van-kessel, A. E. Axel et al., CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma, Blood, vol.128, pp.959-970, 2016.

M. Pick, V. Vainstein, N. Goldschmidt, D. Lavie, D. Libster et al., Daratumumab resistance is frequent in advanced-stage multiple myeloma patients irrespective of CD38 expression and is related to dismal prognosis, Eur. J. Haematol, vol.100, pp.494-501, 2018.

A. Kitadate, H. Kobayashi, Y. Abe, K. Narita, D. Miura et al., CD38 Expression Levels on Myeloma Cells and the Frequency of Circulating CD38-Positive Treg Cells Are Associated with the Response to Daratumumab in Multiple Myeloma, Blood, vol.132, 1883.

D. Viola, A. Dona, E. G. Gunes, E. Troadec, X. Wu et al., Immune Mediated Mechanisms of Resistance to Daratumumab, vol.132, 2018.

S. L. Topalian, J. M. Taube, R. A. Anders, and E. M. Pardoll, Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy, Nat. Rev. Cancer, vol.16, pp.275-287, 2016.

X. Yan, P. L. Clemens, T. Puchalski, S. Lonial, H. M. Lokhorst et al., Target-Mediated Drug Disposition of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma after Prior Proteasome Inhibitors and Immunomodulatory Drugs: A Population Pharmacokinetic Analysis, Blood, vol.126, 2015.

M. Centanni, D. J. Moes, I. F. Trocóniz, J. Ciccolini, and J. G. Van-hasselt, Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors, Clin. Pharm, vol.58, pp.835-857, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02513473

R. Deng, F. Jin, S. Prabhu, and S. Iyer, Monoclonal antibodies: What are the pharmacokinetic and pharmacodynamic considerations for drug development?, Expert Opin. Drug Metab. Toxicol, vol.8, pp.141-160, 2012.

A. Deslandes, Comparative clinical pharmacokinetics of antibody-drug conjugates in first-in-human Phase 1 studies, vol.6, pp.859-870, 2014.

I. H. Bartelink, E. F. Jones, S. K. Shahidi-latham, P. R. Lee, Y. Zheng et al., Tumor Drug Penetration Measurements Could Be the Neglected Piece of the Personalized Cancer Treatment Puzzle, Clin. Pharmacol. Ther, vol.106, pp.148-163, 2018.

L. Ruiz-cerdá, E. Asín-prieto, Z. P. Parra-guillen, and I. F. Trocóniz, The Long Neglected Player: Modeling Tumor Uptake to Guide Optimal Dosing, Clin. Cancer Res, vol.24, pp.3236-3238, 2018.

L. Rasche, S. S. Chavan, O. W. Stephens, P. H. Patel, R. Tytarenko et al., Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing, Nat. Commun, vol.8, p.268, 2017.

L. Rasche, K. M. Kortüm, M. S. Raab, and N. Weinhold, The Impact of Tumor Heterogeneity on Diagnostics and Novel Therapeutic Strategies in Multiple Myeloma, Int. J. Mol. Sci, 1248.

X. S. Xu, M. A. Dimopoulos, P. Sonneveld, P. J. Ho, A. Belch et al., Pharmacokinetics and Exposure-Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple Myeloma, Adv. Ther, vol.35, pp.1859-1872, 2018.

A. Chillemi, V. Quarona, A. Zito, F. Morandi, D. Marimpietri et al., Generation and Characterization of Microvesicles after Daratumumab Interaction with Myeloma Cells, Blood, vol.126, p.1849, 2015.

J. Krejcik, K. A. Frerichs, I. S. Nijhof, B. Van-kessel, J. F. Van-velzen et al., Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab, Clin. Cancer Res, vol.23, pp.7498-7511, 2017.

J. A. Zonder, A. F. Mohrbacher, S. Singhal, F. Van-rhee, W. I. Bensinger et al., A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma, Blood, vol.120, pp.552-559, 2012.

R. A. Beckman, R. Von-roemeling, and A. M. Scott, Monoclonal antibody dose determination and biodistribution into solid tumors, Ther. Deliv, vol.2, pp.333-344, 2011.

A. S. Strik, Y. C. Wang, L. E. Ruff, W. Yashar, B. T. Messmer et al., Individualized Dosing of Therapeutic Monoclonal Antibodies-A Changing Treatment Paradigm?, AAPS J, vol.20, p.99, 2018.

V. A. Thomas and J. P. Balthasar, Understanding Inter-Individual Variability in Monoclonal Antibody Disposition, vol.8, 2019.

N. J. Gormley and R. Pazdur, Immunotherapy Combinations in Multiple Myeloma-Known Unknowns, N. Engl. J. Med, vol.379, pp.1791-1795, 2018.

D. Day and L. L. Siu, Approaches to modernize the combination drug development paradigm, Genome Med, 2016.

T. Hofmarcher, P. Lindgren, N. Wilking, and B. Jonsson, The cost of cancer in Europe, Eur. J. Cancer, vol.129, pp.41-49, 2018.

D. Romero, To all involved-we have a problem, Nat. Rev. Clin. Oncol, vol.15, 2018.

C. K. Ma, M. Danta, R. Day, and D. D. Ma, Dealing with the spiralling price of medicines: Issues and solutions, Intern. Med. J, vol.48, pp.16-24, 2018.

S. Salas-vega, O. Iliopoulos, and E. Mossialos, Assessment of Overall Survival, Quality of Life, and Safety Benefits Associated With New Cancer Medicines, JAMA Oncol, vol.3, 2017.

J. H. Turner, Theranostic Outcomes in Clinical Practice of Oncology: What, So What, Now What? What's More, Cancer Biother. Radiopharm, vol.34, pp.135-140, 2019.

D. C. Sotelo-rodríguez, A. Ruíz-patiño, L. Ricaurte, O. Arrieta, Z. L. Zatarain-barrón et al., Challenges and shifting paradigms in clinical trials in oncology: The case for immunological and targeted therapies, vol.13, 2019.

A. Hoering, B. Durie, H. Wang, and J. Crowley, End points and statistical considerations in immuno-oncology trials: Impact on multiple myeloma, Future Oncol, vol.13, pp.1181-1193, 2017.

M. Gerwing, K. Herrmann, A. Helfen, C. Schliemann, W. E. Berdel et al., The beginning of the end for conventional RECIST-novel therapies require novel imaging approaches, Nat. Rev. Clin. Oncol, vol.16, pp.442-458, 2019.

M. Nishino, N. H. Ramaiya, H. Hatabu, and F. S. Hodi, Monitoring immune-checkpoint blockade: Response evaluation and biomarker development, Nat. Rev. Clin. Oncol, vol.14, pp.655-668, 2017.

A. Romano, G. A. Palumbo, N. L. Parrinello, C. Conticello, M. Martello et al., Minimal Residual Disease Assessment Within the Bone Marrow of Multiple Myeloma: A Review of Caveats, Clinical Significance and Future Perspectives. Front. Oncol, vol.9, p.699, 2019.

P. Moreau and E. Zamagni, MRD in multiple myeloma: More questions than answers?, Blood Cancer J, vol.7, p.639, 2017.

S. K. Kumar, B. Paiva, K. C. Anderson, B. Durie, O. Landgren et al., International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma, Lancet Oncol, vol.17, pp.328-346, 2016.

G. Van-dongen, G. W. Visser, M. N. Hooge, . -d.;-de, E. G. Vries et al., Immuno-PET: A Navigator in Monoclonal Antibody Development and Applications, Oncology, vol.12, pp.1379-1389, 2007.

M. H. Guang, A. Mccann, G. Bianchi, L. Zhang, P. Dowling et al., Overcoming multiple myeloma drug resistance in the era of cancer 'omics, vol.59, pp.542-561, 2017.

F. Kraeber-bodere, C. Bailly, M. Chérel, and J. Chatal, ImmunoPET to help stratify patients for targeted therapies and to improve drug development, Eur. J. Nucl. Med. Mol. Imaging, vol.43, pp.2166-2168, 2016.
URL : https://hal.archives-ouvertes.fr/inserm-01809742

W. Wei, Z. T. Rosenkrans, J. Liu, G. Huang, Q. Luo et al., ImmunoPET: Concept, Design, and Applications, Chem. Rev, vol.120, pp.3787-3851, 2020.

B. N. Mcknight and N. Viola, 89Zr-ImmunoPET companion diagnostics and their impact in clinical drug development, J. Label. Compd. Radiopharm, vol.61, pp.727-738, 2018.

A. Ghai, D. Maji, N. Cho, C. Chanswangphuwana, M. Rettig et al., Preclinical Development of CD38-Targeted [89Zr]Zr-DFO-Daratumumab for Imaging Multiple Myeloma, J. Nucl. Med, vol.59, pp.216-222, 2017.

E. Caserta, J. Chea, M. Minnix, E. K. Poku, D. Viola et al., Copper 64-labeled daratumumab as a PET/CT imaging tracer for multiple myeloma, Blood, vol.131, pp.741-745, 2018.

G. Ulaner, N. Sobol, J. O'donoghue, E. Burnazi, K. Staton et al., Preclinical development and First-in-human imaging of 89Zr-Daratumumab for CD38 targeted imaging of myeloma, J. Nucl. Med, p.203, 2019.

N. Pandit-taskar, Functional Imaging Methods for Assessment of Minimal Residual Disease in Multiple Myeloma: Current Status and Novel ImmunoPET Based Methods, Semin. Hematol, vol.55, pp.22-32, 2018.

G. A. Ulaner, N. B. Sobol, J. A. O'donoghue, A. S. Kirov, C. C. Riedl et al., CD38-targeted Immuno-PET of Multiple Myeloma: From Xenograft Models to First-in-Human Imaging, Radiology, vol.295, pp.606-615, 2020.

C. Bailly, C. Bodet-milin, M. Bourgeois, S. Gouard, C. Ansquer et al., Exploring Tumor Heterogeneity Using PET Imaging: The Big Picture, Cancers, vol.11, p.1282, 2019.
URL : https://hal.archives-ouvertes.fr/inserm-02318425

F. Bensch, E. L. Van-der-veen, M. N. Hooge, L. Jorritsma-smit, A. Boellaard et al., atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer, Nat. Med, vol.24, pp.1852-1858, 2018.

A. N. Niemeijer, D. Leung, M. C. Huisman, I. Bahce, O. S. Hoekstra et al., Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer, Nat. Commun, vol.9, p.4664, 2018.

E. C. Dijkers, T. H. Munnink, J. G. Kosterink, A. H. Brouwers, P. L. Jager et al., Biodistribution of 89Zr-trastuzumab and PET Imaging of HER2-Positive Lesions in Patients With Metastatic Breast Cancer, Clin. Pharmacol. Ther, vol.87, pp.586-592, 2010.

K. Muylle, P. Flamen, D. J. Vugts, T. Guiot, G. Ghanem et al., Tumour targeting and radiation dose of radioimmunotherapy with (90)Y-rituximab in CD20+ B-cell lymphoma as predicted by (89)Zr-rituximab immuno-PET: Impact of preloading with unlabelled rituximab, Eur. J. Nucl. Med. Mol. Imaging, vol.42, pp.1304-1314, 2015.

C. W. Oordt, M. D. Mcgeoch, A. Bergstrom, M. Mcsherry, I. Smith et al., Immuno-PET Imaging to Assess Target Engagement: Experience from 89Zr-Anti-HER3 mAb (GSK2849330) in Patients with Solid Tumors, J. Nucl. Med, vol.60, pp.902-909, 2019.

C. Bailly, S. Gouard, F. Guérard, B. Chalopin, T. Carlier et al., What is the Best Radionuclide for Immuno-PET of Multiple Myeloma? A Comparison Study Between 89Zr-and 64Cu-Labeled Anti-CD138 in a Preclinical Syngeneic Model, Int. J. Mol. Sci, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02141555

S. K. Sharma, A. Chow, S. Monette, D. Vivier, J. Pourat et al., Fc-Mediated Anomalous Biodistribution of Therapeutic Antibodies in Immunodeficient Mouse Models, Cancer Res, vol.78, pp.1820-1832, 2018.

J. Paton-hough, A. Chantry, and M. A. Lawson, A review of current murine models of multiple myeloma used to assess the efficacy of therapeutic agents on tumour growth and bone disease, vol.77, pp.57-68, 2015.

R. D. Sanderson and Y. Yang, Syndecan-1: A dynamic regulator of the myeloma microenvironment, Clin. Exp. Metastasis, vol.25, pp.149-159, 2007.

M. Cavo, E. Terpos, C. Nanni, P. Moreau, S. Lentzsch et al., Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: A consensus statement by the International Myeloma Working Group, Lancet Oncol, vol.18, pp.206-217, 2017.

D. J. Green and O. Press, Whither radioimmunotherapy: To be or not to be? Cancer Res, vol.77, pp.2191-2196, 2017.

S. N. Rizvi, O. J. Visser, M. J. Vosjan, A. Van-lingen, O. S. Hoekstra et al., Biodistribution, radiation dosimetry and scouting of 90Y-ibritumomab tiuxetan therapy in patients with relapsed B-cell non-Hodgkin's lymphoma using 89Zr-ibritumomab tiuxetan and PET, Eur. J. Nucl. Med. Mol. Imaging, vol.39, pp.512-520, 2012.

F. Morschhauser, J. Radford, A. Van-hoof, U. Vitolo, P. Soubeyran et al., Phase III Trial of Consolidation Therapy With Yttrium-90-Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma, J. Clin. Oncol, vol.26, pp.5156-5164, 2008.

T. E. Witzig, I. W. Flinn, L. I. Gordon, C. Emmanouilides, M. S. Czuczman et al., Treatment With Ibritumomab Tiuxetan Radioimmunotherapy in Patients With Rituximab-Refractory Follicular Non-Hodgkin's Lymphoma, J. Clin. Oncol, vol.20, pp.3262-3269, 2002.

A. Martínez, M. Martínez-ramirez, D. Martínez-caballero, P. Beneit, J. Clavel et al., Radioinmunoterapia en el linfoma no Hodgkin, posicionamiento

, Experiencia y seguimiento a los 10 años, Revista Española de Medicina Nuclear e Imagen Molecular, vol.36, pp.13-19, 2017.

C. W. Scholz, A. Pinto, W. Linkesch, O. Lindén, A. Viardot et al., 90Yttrium-Ibritumomab-Tiuxetan as First-Line Treatment for Follicular Lymphoma: 30 Months of Follow-Up Data From an International Multicenter Phase II Clinical Trial, J. Clin. Oncol, vol.31, pp.308-313, 2013.

K. Hohloch, Radioimmunotherapy of lymphoma: An underestimated therapy option, Lancet Haematol, vol.4, pp.6-7, 2017.

T. Illidge, . Radioimmunotherapy, and . Lymphoma, A Treatment Approach Ahead of Its Time or Past Its Sell-By Date?, J. Clin. Oncol, vol.28, pp.2944-2946, 2010.

E. Dadachova, Cancer Therapy with Alpha-Emitters Labeled Peptides, Semin. Nucl. Med, vol.40, pp.204-208, 2010.

N. Fichou, S. Gouard, C. Maurel, J. Barbet, L. Ferrer et al., Single-Dose Anti-CD138 Radioimmunotherapy: Bismuth-213 is More Efficient than Lutetium-177 for Treatment of Multiple Myeloma in a Preclinical Model
URL : https://hal.archives-ouvertes.fr/inserm-01817464

S. Gouard, B. Chalopin, C. Saï-maurel, F. Guérard, L. Navarro et al., Efficacy of Astatine-211 Radioimmunotherapy of Multiple Myeloma Using an Anti-mCD138 Monoclonal Antibody in a Syngeneic Murine Model, Eur. J. Nucl. Med. Mol. Imaging, vol.45, pp.166-167, 2018.
URL : https://hal.archives-ouvertes.fr/inserm-02341491

S. Gouard, A. Pallardy, J. Gaschet, A. Faivre-chauvet, F. Bruchertseifer et al., Comparative analysis of multiple myeloma treatment by CD138 antigen targeting with bismuth-213 and Melphalan chemotherapy, Nucl. Med. Boil, vol.41, pp.30-35, 2014.

M. Chérel, S. Gouard, J. Gaschet, C. Saï-maurel, F. Bruchertseifer et al.,

, Monoclonal Antibody in a Murine Model of Multiple Myeloma, J. Nucl. Med, vol.54, pp.1597-1604, 2013.

C. Bailly, S. Gouard, M. Lacombe, P. R. Saec, B. .-l.;-chalopin et al., Comparison of Immuno-PET of CD138 and PET imaging with 64CuCl2 and 18F-FDG in a preclinical syngeneic model of multiple myeloma, Oncotarget, vol.9, pp.9061-9072, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01677118